In our industry, we're a bit of two minds about that. We have some issues with the patent regime in the U.S. Our whole ICT industry down there is suffering, so in that sense the Canadian regime is better.
On the copyright side, we have a copyright act that predates the Internet era. That's obviously a gap. In today's economy, non-tangible property is displacing bricks and mortar and physical things as the driver of economic growth and wealth, and we need to update our copyright laws to reflect that.
I'm acutely aware of the fact that the issue has been quite controversial and that at some point there seem to be views that are too extreme, but as Canadians, we're reasonable people. We actually believe that work can be done. We actually believe that we can put something through a committee and come out with something that will put us into the Internet age, address many of the issues, and resolve a lot of the differences, and frankly, you have to reach a point where the views of people who want to be unreasonable simply have to be put aside. That's one area.
We know there's a different situation in the biotech area. Regulatory regimes are quite different, and so is intellectual property. In our case, we live in a world in which things change very fast. We live in a world in which a particular apparatus, like the BlackBerry, probably has a hundred patents on it. In systems like the U.S. patent regime, if you have a challenge on one one-hundredth of the apparatus, you can capture all the revenue made from a whole system, so we have issues there.
That being said, BIOTEC may have some separate issues.